As of 2026-06-26, AN2 Therapeutics, Inc. Common Stock (ANTX) has a 3-month relative strength percentile of 88 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 96. The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 9.6%, relative volume 14.24×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Daily range, ATR, beta, and the math for a 1-ADR stop.
ADR% (20d)avg daily range
9.6%Elevated
ATR(14)14-day EMA
$0.43
ATR%ATR as % of close
8.23%
Beta vs SPY90d rolling
0.21
1-ADR stoprisk from close $5.20
$4.70−9.6%
COMPUTED · AS OF 2026-06-26
Pattern read
ANTX is in a stage 2 uptrend, week 3. Currently in a 75-day base; basing ADR 10.4% (broad 8.8%). VCP detected: inconclusive. RS line below base-start high. Distance from 50d / 200d: 15.7% / 118.2%.
Pure factual computation. Not a recommendation. See stage analysis.
Strong relative strength, but attention is quiet relative to this name’s own recent norm. Academic work links low public attention to better forward returns on average — context to weigh, not a forecast.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
ANTX ranks at the 82th percentile over 1 month, 88th percentile over 3 months, 99th percentile over 6 months, 97th percentile over 1 year against the full TickerStance CS+ADRC universe of U.S. equities.
ANTX is classified under the Healthcare sector within the Pharmaceutical Products industry per the TickerStance sector-classification pipeline, which maps U.S. equities to GICS-aligned sectors using exchange SIC codes and Massive Finance reference data.
Sector RS percentile is not available for Healthcare at this snapshot. Leading sector status (threshold: Healthcare RS ≥ 70th percentile) cannot be determined until the next sector RS pipeline run.
ANTX currently shows a 20-day average daily range (ADR%) of 9.6%, a 90-day beta versus the S&P 500 of 0.21. An ADR% above 4% indicates an intraday swing-trading eligible name in the Minervini Volatility Contraction Pattern framework. ADR% and ATR% are updated daily; beta is computed over a trailing 90-day window.
TickerStance computes ANTX's month-by-month seasonality from its full daily price history: the average and median return for each calendar month, how often that month closed higher, and the best and worst months on record. These are historical frequencies, not forecasts — a strong seasonal month describes what ANTX has tended to do in prior years, not a prediction of what comes next. The full month-by-month heatmap and win-rate table sit higher on this page.
ANTX most recently filed a 10-Q covering FY26 Q1 with the SEC on 2026-05-11. TickerStance sources earnings data from SEC EDGAR XBRL submissions and updates the fundamentals panel daily. The Pro dossier shows eight quarters of EPS and revenue trend, operating margin history, and a composite earnings-quality rank.
§ Seasonality
10y · since 2022
Best monthMaron averageavg +56.69% · 75% win · n 4
Worst monthFebon averageavg -23.61% · 0% win · n 4